Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00477945
Other study ID # 0704-29 IUCRO-0187
Secondary ID
Status Completed
Phase Phase 1
First received May 22, 2007
Last updated September 10, 2014
Start date May 2007
Est. completion date November 2010

Study information

Verified date September 2014
Source Indiana University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This is a phase I trial to determine the maximum tolerated dose (MTD) of clofarabine in a combination with high-dose etoposide and cyclophosphamide. This is an initial step in developing a novel myeloablative preparative regimen for autologous hematopoietic stem cell transplantation (ASCT). While this phase I trial will initially develop the regimen in patients with refractory disease, it is expected that it will find its best application in patients with less advanced disease.


Description:

All patients will receive the same doses of etoposide and cyclophosphamide. The dose of clofarabine will be escalated in successive cohorts of patients. Using a standard dose escalation design, successive cohorts of 3 patients will be treated with escalating doses of clofarabine (see Section 5.5 below). At the MTD (or highest dose-level if the MTD is not reached), the cohort will be expanded to 10 patients to better investigate correlative studies and give some preliminary idea of efficacy.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date November 2010
Est. primary completion date November 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

1. Documentation of disease. Patients must have one of the following disease types:

- Diffuse large cell non-Hodgkin's lymphoma, mediastinal B-cell lymphoma, or peripheral T-cell lymphoma that is:

- Primary refractory (achievement less than complete response)

- Relapsed and refractory (achievement less than a partial response) to at least a single salvage therapy

- Relapsed or primary refractory Follicular lymphoma (FL) with a high FL International Prognostic Index.

- Large cell transformation of lymphoma from a more indolent lymphoma (e.g., follicular, marginal zone, etc.)

- Mantle cell lymphoma that is:

- Primary Refractory (achievement less than complete response)

- Relapsed (regardless of chemosensitivity of relapsed disease)

2. Patients who received prior autologous stem cell transplantation are not eligible.

3. Patient age 18-70 years

4. Performance status ECOG 0-1

5. Required baseline laboratory values:

- LVEF > 45% corrected

- DLCO > 50% of predicted value (corrected for hemoglobin)

- Serum creatinine = 2.0 mg/dl or estimated creatinine clearance of =60 ml/min

- Bilirubin < 1 x upper limit of normal value.

- AST and ALT < 1 x upper limit of normal value.

6. Signed written informed consent. Patient must be capable of understanding the investigational nature of the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent

Exclusion Criteria:

1. No active infection. Patients with active infections requiring oral or intravenous antibiotics are not eligible for enrollment until resolution of infection.

2. No HIV disease. Patients with immune dysfunction are at a significantly higher risk of infection from intensive immunosuppressive therapies.

3. Non-pregnant and non-nursing. Treatment under this protocol would expose a fetus to significant risks. Women of childbearing potential should have a negative pregnancy test prior to study entry. Women and men of reproductive potential should agree to use an appropriate method of birth control throughout their participation in this study due to the teratogenic potential of the therapy utilized in this trial. Appropriate methods of birth control include oral contraceptives, implantable hormonal contraceptives (NorplantĀ®), or double barrier method (diaphragm plus condom).

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
clofarabine
Cohort N Clofarabine (mg/m2/day) 3-6 30 3-6 40 3-6 50 3-6 60 6-10 70

Locations

Country Name City State
United States Indiana University Cancer Center Indianapolis Indiana

Sponsors (2)

Lead Sponsor Collaborator
Indiana University School of Medicine Genzyme, a Sanofi Company

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Determine the maximum tolerated dose (MTD) of clofarabine in association with high-dose etoposide and cyclophosphamide followed by ASCT in patients with refractory lymphoma malignancies. 1 yr Yes
Secondary Assessment of the toxicity of the combination of clofarabine, and high-dose etoposide and cyclophosphamide-- Describe engraftment kinetics-- Describe the response rate-- Describe relapse rate and event-free survival-- Assess clofarabine p 1 year Yes
See also
  Status Clinical Trial Phase
Recruiting NCT06014073 - TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL Phase 1/Phase 2
Recruiting NCT02007811 - Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination Phase 1/Phase 2
Terminated NCT00909948 - Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant Phase 1
Completed NCT00665314 - Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM). Phase 2
Recruiting NCT05370547 - Chidamide Bridging for CAR-T Therapy Phase 1/Phase 2
Recruiting NCT06285422 - Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID) Phase 1
Withdrawn NCT01101581 - Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL Phase 1/Phase 2
Terminated NCT00038818 - CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation N/A
Withdrawn NCT01789723 - Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn Phase 1
Completed NCT00013533 - Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies Early Phase 1
Completed NCT01610180 - Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs) Phase 2
Terminated NCT00714259 - Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies Phase 2/Phase 3
Completed NCT01018758 - Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy Phase 2
Completed NCT00001830 - Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants Phase 1
Recruiting NCT01063439 - BuEAM Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat Diffuse Large B Cell Lymphoma (DLCBL) Phase 2
Completed NCT01527422 - Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab Pateinets With Aggresive NHL Phase 1/Phase 2
Completed NCT00834951 - Adjuvant Low Dose Total Body Irradiation in Elderly Patients With Diffuse Large B-Cell Lymphoma Phase 2
Recruiting NCT04497688 - Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma N/A
Completed NCT00597714 - Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant Phase 2
Completed NCT00001430 - A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas Phase 2